Alnylam Pharmaceuticals (ALNY) to Release Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.55) per share and revenue of $584.32 million for the quarter. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts expect Alnylam Pharmaceuticals to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $254.85 on Tuesday. The company’s fifty day moving average is $247.46 and its two-hundred day moving average is $255.63. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12-month low of $143.50 and a 12-month high of $304.39. The company has a market cap of $33.15 billion, a P/E ratio of -117.44 and a beta of 0.30.

Wall Street Analyst Weigh In

Several analysts have issued reports on ALNY shares. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $315.58.

Insider Activity

In other news, CMO Pushkal Garg sold 1,561 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the sale, the chief marketing officer now directly owns 13,537 shares in the company, valued at approximately $3,454,236.29. The trade was a 10.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,392 shares of company stock worth $1,875,627. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A hedge fund recently bought a new stake in Alnylam Pharmaceuticals stock. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,032 shares of the biopharmaceutical company’s stock, valued at approximately $243,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.